A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency

Condition:   Primary Immunodeficiency Interventions:   Biological: Gamunex-C;   Biological: IVIG-PEG Sponsor:   Grifols Therapeutics LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials